Study suggests common drug could be used to prevent certain skin cancers
(Ohio State University Wexner Medical Center) New data published by researchers at The OSUCCC - James suggests that an oral drug currently used in the clinical setting to treat neuromuscular diseases could also help prevent a common form of skin cancer caused by damage from ultraviolet-B radiation from the sun. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2021 Category: Cancer & Oncology Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

NIDCR Science News - April 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. SARS-CoV-2 May Infect the Mouth NIDCR-led study points to role for saliva in spread of virus NIDCR • March 25, 2021 A Safe Space in the Dental Clinic Making dental visits more soothing for children with autism NIDCR • March 23, 2021 How Fungus Finds A Foothold in the Mouth Overactive ...
Source: NIDCR Science News - April 5, 2021 Category: Dentistry Source Type: news

Europe Approves Pemigatinib for Bile Duct Cancer Europe Approves Pemigatinib for Bile Duct Cancer
The oral targeted therapy is for the treatment of locally advanced or metastatic cholangiocarcinoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 31, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

UB awarded $1.5 million to reprogram white blood cells in fight against oral cancer
(University at Buffalo) The University at Buffalo has received a $1.5 million grant from the United States Department of Defense to develop new therapies that help reduce chronic inflammation and immunosuppression in oral cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2021 Category: International Medicine & Public Health Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

Oral Health Should be a Development Priority
Photo by Bekky Bekks on Unsplash By Adekemi AdeniyanEKITI, Nigeria, Mar 19 2021 (IPS) The mouth is a barometer of social inequities — it reflects the injustices in our society. As George Cuvier, an 18th century naturalist said: “Show me your teeth, and I will tell you who you are”. To me, as a dentist, the mouth is like a microscope that reveals more than just tooth decay. It exposes us to a world where people lack access to water, health, quality education and live on low income. So, when the FDI World Dental Federation unveils a “Be Proud of Your Mouth” campaign for World Oral Health Day (W...
Source: IPS Inter Press Service - Health - March 19, 2021 Category: International Medicine & Public Health Authors: Adekemi Adeniyan Tags: Africa Headlines Health Poverty & SDGs Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A new type of recyclable: Finding new uses for established drugs
(Tokyo Medical and Dental University) Using cell culture and mouse model approaches, researchers from Tokyo Medical and Dental University (TMDU) have found a novel drug combination that can inhibit tumor growth in oral and esophageal carcinomas. They also identified a potential biomarker that can help predict patient sensitivity to this treatment. These findings provide valuable knowledge for the fight against these deadly cancers and demonstrate a potential new use for drugs currently approved for other diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2021 Category: Cancer & Oncology Source Type: news

Lithium chloride promotes recovery of radiation-induced oral mucositis and dysgeusia
(International& American Associations for Dental Research) Oral mucositis and taste dysfunction (dysgeusia) occurs in nearly all patients receiving head and neck radiotherapy and tremendously affects the quality of life and treatment outcome. The study " LiCl Promotes Recovery of Radiation-Induced Oral Mucositis and Dysgeusia " published in the Journal of Dental Research (JDR), investigated the hypothesis that lithium chloride (LiCl) can promote the restoration of oral mucosa integrity and taste function after radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Oral and maxillofacial reconstruction featured in Journal of the California Dental Association
 Contact: Alicia Malaby916.554.5372alicia.malaby@cda.orgSacramento, Calif. – The March 2021 issue of the Journal of the California Dental Association features the latest advances in oral and maxillofacial reconstruction. Articles discuss dental implants, modern temporomandibular joint surgery, contemporary sleep surgery and the diagnosis and treatment of oral cavity and oropharyngeal cancer.“This issue, followed by an upcoming issue on head and neck cancers, will augment health care providers’ understanding of several technical and complex areas of dentistry,” ...
Source: Dental Technology Blog - March 4, 2021 Category: Dentistry Source Type: news

Mouth cancer: Pain, 'fullness' or ringing in the ears could be signs you’re at risk
MOUTH cancer: Around 8,300 people are diagnosed with mouth cancer each year in the UK, which is about one in every 50 cancers diagnosed. Sensations felt in your ears could indicate your risk of the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - March 1, 2021 Category: Consumer Health News Source Type: news

NYU Oral Cancer Center awarded NIH grant to study interplay between oral cancer and nerves
(New York University) NYU Oral Cancer Center has been awarded a five-year, $3.1 million grant (R01 CA231396) by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The principal investigators, Donna Albertson, PhD, and Brian Schmidt, DDS, MD, PhD, seek to improve oral cancer treatment and alleviate pain by better understanding how a subset of nerves that possess a receptor called TRPV1 on the cell membrane contribute to cancer progression and pain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

Nicotinamide: Safety & Differences From Niacin Nicotinamide: Safety & Differences From Niacin
Nicotinamide, a form of vitamin B3, is an oral treatment option for actinic keratosis, squamous and basal cell carcinomas, and bullous pemphigoid. How does it relate to niacin--and how is it used?Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

You May Be Surprised by the Type of American Who is Postponing Basic Health Care During the Pandemic
There’s more than one way to get sick during the COVID-19 pandemic. You can contract the virus, of course, as more than 28 million Americans already have. Or you can dodge the disease but still suffer from the disruption caused by quarantines and social distancing, if they lead you to neglect routine health care. That, a new TIME-Harris Poll survey shows, is just what too many of us are doing. ( function() { var func = function() { var iframe = document.getElementById('wpcom-iframe-15f249b5273bbd9b00ac5da4e954d4a6') if ( iframe ) { iframe.onload = function() { iframe.contentWindow.postMe...
Source: TIME: Health - February 23, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

Theragnostics, German hospital to study THG-008 for PET
Theragnostics and Essen University Hospital in Germany will study the investigationa...Read more on AuntMinnie.comRelated Reading: SBI, Theragnostics ink oral cancer technology deal GE, Theragnostics partner on PSMA agent Theragnostics inks AstraZeneca agreement (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 17, 2021 Category: Radiology Source Type: news

Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand
In a regulatory filing, Glenmark Pharma said it launched "SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP (maximum retail price) compared to the innovator brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5 mg) per month". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 16, 2021 Category: Pharmaceuticals Source Type: news

Many Babies Acquire Oral HPV, Probably From Mom
THURSDAY, Feb. 11, 2021 -- Cancer-causing human papillomavirus (HPV) is considered a sexually transmitted infection, but a new study shows that many babies are born carrying the virus in their mouths. " In brief, HPV infection can be acquired at... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 11, 2021 Category: General Medicine Source Type: news

BrainCool AB (publ) Receives FDA "Breakthrough Device" Designation for Cooral(R) System for Prevention of Oral Mucositis
Recent Medicare Reimbursement Ruling Provides an Additional Boost in Paving the Way for Elimination of One of the Severest Side-Effects of Cancer Treatment LUND, Sweden, Feb. 11, 2021 -- (Healthcare Sales & Marketing Network) -- BrainCool AB (publ), a ... Devices, FDA BrainCool, Cooral, hypothermia, oral mucositis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2021 Category: Pharmaceuticals Source Type: news

Unlocking the mystery behind skeletal aging
This study is the first in vivo research to demonstrate that the loss of an epigenetic factor promotes adult stem cell deterioration and exhaustion in skeletal aging.The findings, the researchers say, hold promise for the eventual development of strategies to reverse bone-fat imbalance, as well as for new prevention and treatment methods that address skeletal aging and osteoporosis by rejuvenating adult stem cells.“The work of Dr. Wang, his lab members and collaborators provides new molecular insight into the changes associated with skeletal aging,” said Dr. Paul Krebsbach, dean of the UCLA School of Dentistry....
Source: UCLA Newsroom: Health Sciences - February 10, 2021 Category: Universities & Medical Training Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

NYU Dentistry awarded NIH grant to investigate oral cancer pain treatment utilizing co-delivery of DNA and RNA
Clinician-scientists Seiichi Yamano and Brian Schmidt to further novel gene therapy strategy to treat oral cancer painNew York UniversityGrant AnnouncementNYU College of Dentistry clinician-scientists Seiichi Yamano and Brian Schmidt have set out to develop a new class of medicines using gene therapy to effectively and safely treat oral cancer pain. The National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), has awarded the researchers a five-year, $2.9 million grant (R01DE029694) to test whether nonviral co-delivery of DNA and RNA will safely alleviate oral cancer p...
Source: Dental Technology Blog - February 8, 2021 Category: Dentistry Source Type: news

Oral Contraceptives May Reduce Cancer Risk
Oral Contraceptives May Reduce Ovarian and Endometrial Cancer Risk (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 5, 2021 Category: General Medicine Source Type: news

Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduce Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk Oral Contraceptives Reduces Ovarian and Endometrial Cancer Risk
Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 4, 2021 Category: Internal Medicine Tags: Hematology-Oncology News Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings sho...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

NYU Dentistry awarded NIH grant to investigate oral cancer pain treatment utilizing co-delivery of DNA and RNA
(New York University) NYU College of Dentistry clinician-scientists Seiichi Yamano and Brian Schmidt have set out to develop a new class of medicines using gene therapy to effectively and safely treat oral cancer pain. The National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), has awarded the researchers a five-year, $3,276,000 grant to test whether nonviral co-delivery of DNA and RNA will safely alleviate oral cancer pain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2021 Category: Cancer & Oncology Source Type: news

Oral Contraceptives and Cancer: New Data Oral Contraceptives and Cancer: New Data
Dr Andrew Kaunitz breaks down a new study that examines the link between oral contraceptives and cancer.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news

Dental Practices Rebound as U.S. Dentists Look Forward to COVID-19 Vaccine
Full article click hereWEDNESDAY, Jan. 20, 2021 -- Thecoronavirus pandemic hit dental practices hard early in 2020, as COVID-19 fears kept millions of Americans from seeking routine oral health care.But as dental offices have ratcheted up their safety measures, more patients have steadily been returning for checkups and more, according to recent polls conducted by the American Dental Association Health Policy Institute (HPI).In fact, by Dec. 14 the average patient volume at U.S. dental offices had resurged to 78% of pre-coronavirus levels according to the poll, which involved 2,700 dentists nationwide.One such dentist agre...
Source: Dental Technology Blog - January 27, 2021 Category: Dentistry Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Mouth cancer: Having a difficulty swallowing food could be an indication of the disease
MOUTH cancer: The deadly disease can offer some early clues in a number of ways with a difficulty swallowing being one of them. (Source: Daily Express - Health)
Source: Daily Express - Health - January 25, 2021 Category: Consumer Health News Source Type: news

How Much Does Drinking Alcohol Contribute to US Cancer Burden? How Much Does Drinking Alcohol Contribute to US Cancer Burden?
Alcohol consumption accounts for 4.8% of all cancer cases overall, but this rises to 12.1% of female breast cancer, 11% of colorectal cancer, and more than 45% of mouth and throat cancers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ORGOVYX (relugolix), the First FDA-Approved Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer, Available at Biologics by McKesson
CARY, N.C., Jan. 21, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Myovant Sciences as a specialty pharmacy provider for ORGOVYXTM (relugolix) for the treatment of advanced prostate cancer. (Source: McKesson News)
Source: McKesson News - January 21, 2021 Category: Information Technology Source Type: news

FDA grants priority review to Roche ’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease
Basel, 21 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.“Since its US approval, Esbriet has become a standard of care for people living with idiopathic pulmonary fibrosis. However, significant unmet need remains in fibrotic lung diseases, including unclassifiable interstitial lung disease ...
Source: Roche Investor Update - January 21, 2021 Category: Pharmaceuticals Source Type: news

STUDY: Long term mask use breeds microbes that infiltrate the lungs and contribute to advanced stage lung cancer
(Natural News) A new study finds that cultivation and enrichment of microbes on the face can infiltrate the lungs through unconscious aspirations and cause inflammatory responses and advanced stage lung cancer. The nose and the mouth were designed to take in oxygen without strain, uninhibited. The oxygen travels down the trachea and splits off into... (Source: NaturalNews.com)
Source: NaturalNews.com - January 15, 2021 Category: Consumer Health News Source Type: news

Behaviors surrounding oral sex may increase HPV-Related cancer risk
(Johns Hopkins Medicine) A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

Esophageal cancer patients show abundance of oral pathogens
(Tokyo Medical and Dental University) DNA from various oral bacterial pathogens has been found in tumors from esophageal cancer patients. Researchers led by Tokyo Medical and Dental University (TMDU) examined bacterial pathogens in plaque and saliva from esophageal cancer patients, determining that a prevalence of three species in particular, along with alcohol consumption, is associated with a high risk of esophageal cancer. Screening of oral pathogens could therefore be used for early disease detection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2021 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study Outlines Role of Oral Sex in Rare Throat, Mouth Cancers
  TUESDAY, Jan. 12, 2021 -- People who began having oral sex at a young age or at greater " intensity " may face an increased risk of a type of throat cancer, a new study finds. The study, published online Jan. 11 in the journal Cancer, focused... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 12, 2021 Category: General Medicine Source Type: news

Oral sex frequency, number of partners linked to HPV-related cancer risk in study
Having more than 10 oral sex partners over a lifetime quadruples a person's risk for human papillomavirus-related mouth and throat cancer, a study published Monday by the journal Cancer found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 11, 2021 Category: Consumer Health News Source Type: news

Toxins In Marijuana Smoke May Be Harmful To Health, Dana-Farber Study Finds
(CNN) — Smoking weed may expose you to the same type of toxic chemicals found in tobacco smoke, a new study finds. People who only smoked marijuana had higher blood and urine levels of several smoke-related toxins such as naphthalene, acrylamide and acrylonitrile than nonsmokers, according to the study published Monday in the journal EClinicalMedicine. Naphthalene is associated with anemia, liver and neurological damage, while acrylamide and acrylonitrile have been associated with cancer and other health issues. “Marijuana use is on the rise in the United States with a growing number of states legalizing it for...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 11, 2021 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN Dana Farber Cancer Institute Marijuana Source Type: news

HPV Throat Cancer and Oral Sex at Younger Age, Multiple Partners HPV Throat Cancer and Oral Sex at Younger Age, Multiple Partners
Engaging in oral sex at a younger age and having more partners in a shorter period were associated with higher risks of developing human papillomavirus (HPV)-related oropharyngeal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Timing, Intensity of Oral Sex Are Risk Factors for HPV-OPC
MONDAY, Jan. 11, 2021 -- In addition to number of oral sex partners, timing and intensity of oral sex are independent risk factors for human papillomavirus-related oropharyngeal cancer (HPV-OPC), according to a study published online Jan. 11 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2021 Category: Pharmaceuticals Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Timing and intensity of oral sex may affect risk of oropharyngeal cancer
(Wiley) Human papillomavirus (HPV) can infect the mouth and throat to cause cancers of the oropharynx. A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, has found that having more than 10 prior oral sex partners was associated with a 4.3-times greater likelihood of having HPV-related oropharyngeal cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Oral Contraceptives Tied to Lower Risk for Certain Cancers
The drugs may increase the risk of breast cancer, but may lower the risk of ovarian and endometrial cancers. (Source: NYT Health)
Source: NYT Health - January 5, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Ovarian Cancer Breast Cancer Women and Girls Deaths (Fatalities) Birth Control and Family Planning Source Type: news

Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news